Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain Oct 31, 2017
Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma Oct 11, 2017
Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain Sep 27, 2017
Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer Sep 11, 2017
Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Sep 05, 2017
Fortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Sep 05, 2017
